Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
JAMA Oncology|August 4, 2018
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinibDaniel B Costa, Kim-Son H Nguyen, Byoung C Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung CancerLorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
Nature Genetics|October 17, 2006
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cellsUlrich Steidl, Frank Rosenbauer, Roel G W Verhaak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2018
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung CancerNathan A Pennell, Joel W Neal, Jamie E Chaft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
Journal of Oncology Practice|May 2, 2012
Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer centerKim-Son H Nguyen, Rachel A Sanford, Mark S Huberman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
The Journal of Clinical Investigation|August 19, 2007
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemiaUlrich Steidl, Christian Steidl, Alexander Ebralidze, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
JAMA Oncology|August 4, 2018
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinibDaniel B Costa, Kim-Son H Nguyen, Byoung C Cho, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain MetastasesDaniel B Costa, Alice T Shaw, Sai-Hong I Ou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2018
Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung CancerLorena Ostios-Garcia, Jennifer Faig, Giulia C Leonardi, et al.
Nature Genetics|October 17, 2006
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cellsUlrich Steidl, Frank Rosenbauer, Roel G W Verhaak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2018
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung CancerNathan A Pennell, Joel W Neal, Jamie E Chaft, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
Journal of Oncology Practice|May 2, 2012
Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer centerKim-Son H Nguyen, Rachel A Sanford, Mark S Huberman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerAnna F Farago, Long P Le, Zongli Zheng, et al.
The Journal of Clinical Investigation|August 19, 2007
A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemiaUlrich Steidl, Christian Steidl, Alexander Ebralidze, et al.
Pageof 18